References
Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma, 3rd English edition. Gastric Cancer. 1998;1:10–24.
Kodera Y, Ito S, Mochizuki Y, et al. Long-term follow up of patients who were positive for peritoneal lavage cytology: final report from the CCOG0301 study. Gastric Cancer. 2012;15(3):335–7.
Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008; 9: 215–21.
Yamaguchi T, Takashima A, Nagashima K, et al. Efficacy of postoperative chemotherapy after resection that leaves no macroscopically visible disease of gastric cancer with positive peritoneal lavage cytology (CY1) or localized peritoneum metastasis (P1a): A multicenter retrospective study. Ann Surg Oncol. 2019. https://doi.org/10.1245/s10434-019-07697-x
Nakayama I, Chin K, Matsushima T, Takahari D, et al. Retrospective comparison of S 1 plus cisplatin versus S 1 monotherapy for the treatment of advanced gastric cancer patients with positive peritoneal cytology but without gross peritoneal metastasis. Int J Clin Oncol. 2017;22:1060–8.
Kano Y, Kosugi S, Ishikawa T, et al. Prognostic significance of peritoneal lavage cytology at three cavities in patients with gastric cancer. Surgery. 2015;158(6):1581–9.
Yoshiaki Iwasaki, Masanori Terashima, Junki Mizusawa, et al. Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer: Japan Clinical Oncology Group study (JCOG0501). 2018 ASCO Annual Meeting, J Clin Oncol. 2018;36(suppl; abstr 4046).
Manzanedo I, Pereira F, Rihuete Caro C et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer with peritoneal carcinomatosis: multicenter study of Spanish Group of Peritoneal Oncologic Surgery (GECOP). Ann Surg Oncol. 2019;26:2615–21.
Ishigami H, Fujiwara Y, Fukushima R, et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol. 2018 Jul 1;36(19):1922–9.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
Dr. Boku reports support from Ono and Taiho (research grant, honorarium) and from Bristol-Myers Squibb, Chugai, and Eli-Lilly (honorarium). The other authors report no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This ASO Author Reflections is a brief invited commentary on the article “Efficacy of Postoperative Chemotherapy after Resection that Leaves No Macroscopically Visible Disease of Gastric Cancer with Positive Peritoneal Lavage Cytology (CY1) or Localized Peritoneum Metastasis (P1a): a Multicenter Retrospective Study,” Ann Surg Oncol. (2019). https://doi.org/10.1245/s10434-019-07697-x.
Rights and permissions
About this article
Cite this article
Yamaguchi, T., Takashima, A. & Boku, N. ASO Author Reflections: What Is the Best Treatment for Gastric Cancer with Positive Peritoneal Lavage Cytology or Localized Peritoneum Metastasis?. Ann Surg Oncol 27 (Suppl 3), 737–738 (2020). https://doi.org/10.1245/s10434-019-08054-8
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-019-08054-8